ReviewJournal of epidemiology and community health2005
Cost effectiveness of statins in coronary heart disease.
Review in Journal of epidemiology and community health, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding.BMJ open · 2017Pooled it
- Pooled it
- Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States.BMC research notes · 2012Pooled it
- Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany.Clinical research in cardiology : official journal of the German Cardiac Society · 2008Trial
- Article
- The need for "gentle medicine" in a post Covid-19 world.Medicine, health care, and philosophy · 2021Review
- Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature.The European journal of health economics : HEPAC : health economics in prevention and care · 2016Review
- Prevalence of dyslipidemia and its association with other coronary artery disease risk factors among urban population in Southeast of Iran: results of the Kerman coronary artery disease risk factors study (KERCADRS).Journal of diabetes and metabolic disorders · 2016Article
- Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.Arquivos brasileiros de cardiologia · 2015Article
- Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications.Science and engineering ethics · 2012Article
- Targeted versus universal prevention. a resource allocation model to prioritize cardiovascular prevention.Cost effectiveness and resource allocation : C/E · 2011Article
- Predicting the effectiveness of prevention: a role for epidemiological modeling.The journal of primary prevention · 2008Article
- Spiralling Medical Costs: Why Canada Needs NICE Medicine.Healthcare policy = Politiques de sante · 2007Article
- Sex differences in the effectiveness of statins after myocardial infarction.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2007Article
- Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention.Journal of epidemiology and community health · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStatin therapy reduces the rate of coronary heart disease, but high costs in combination with a large population eligible for treatment ask for priority setting. Although trials agree on the size of the benefit, economic analyses of statins report contradictory results. This article reviewed cost effectiveness analyses of statins and sought to synthesise cost effectiveness ratios for categories of risk of coronary heart disease and age.
methodsThe review searched for studies comparing statins with no treatment for the prevention of either cardiovascular or coronary heart disease in men and presenting cost per years of life saved as outcome. Estimates were extracted, standardised for calendar year and currency, and stratified by categories of risk, age, and funding source
results24 studies were included (from 50 retrieved), yielding 216 cost effectiveness ratios. Estimated ratios increase with decreasing risk. After stratification by risk, heterogeneity of ratios is large varying from savings to $59 000 per life year saved in the highest risk category and from 6500 dollars to 490,000 dollars in the lowest category. The pooled estimates show values of 21571 dollars per life year saved for a 10 year coronary heart disease risk of 20% and 16862 dollars per life year saved for 10 year risk of 30%.
conclusionStatin therapy is cost effective for high levels of risk, but inconsistencies exist at lower levels. Although the cost effectiveness of statins depends mainly on absolute risk, important heterogeneity remains after adjusting for absolute risk. Economic analyses need to increase their transparency to reduce their vulnerability to bias and increase their reproducibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.